Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study.
Management of Coinfection with HIV-1 and Hepatitis B or C Virus Brook G, Main J, Nelson M, Bhagani S, Wilkins E, Leen C, Fisher M, Gilleece Y, Gilson R, Freedman A, Kulasegaram R, Agarwal K, Sabin C, and Deacon-Adams C on behalf of the BHIVA Viral Hepatitis Working Group. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and CColvin H and Mitchell A, Editors.
Board on Population Health and Public Health Practice, Institute of Medicine. Hepatitis C and HIV Coinfection: Expanding Access through the Ryan White CARE Act U. Department of Health and Human Services, Health Resources and Services Administration, HIV/AIDS Bureau. The purpose of this publication is to help Ryan White Comprehensive AIDS Resources Emergency (CARE) Act planners, administrators, and providers address barriers to care faced by those in need, and construct a response to HIV/HCV coinfection that reflects the current standard of care.
HIV, Hepatitis, Abscesses, and Social Suffering Among Homeless Addicts: Anthropological and Clinical Perspectives Presentation by Philippe Bourgois and Barry Zevin at the University of California San Francisco, November 9, 1998.
In a 2006 multinational cohort of more than 25,000 HIV-infected persons in the United States and Europe, 14% of deaths were liver related and, of those, 66% occurred in persons with concomitant HCV infection.(4)HCV is transmitted via percutaneous contact with HCV-infected blood, most commonly via shared injection drug use (IDU) equipment or contaminated blood products (before the implementation of effective screening of blood banks) or hospital equipment.
A national nonprofit organization dedicated to the prevention, treatment, and cure of hepatitis and other liver diseases through research, education, and advocacy on behalf of those at risk of or affected by liver disease.
A nonprofit organization dedicated to finding a cure and improving the quality of life of those affected by hepatitis B worldwide through research, education, and patient advocacy.
Hepatitis C virus (HCV) infection occurs commonly among HIV-infected individuals, with approximately 20% of HIV-infected persons worldwide estimated to have concurrent chronic HCV infection.(1) HCV prevalence varies substantially among risk groups, with prevalences of 50-90% in cohorts of injection drug users in the United States and Europe (2) and up to 85% in hemophiliacs with HIV.(3) Hepatic disease has become the leading non-AIDS cause of morbidity and mortality among HIV-infected individuals after the availability of antiretroviral therapy (ART) became widespread in resource-sufficient areas of the world.
“If these medicines were made widely available, you could make a plan to eliminate this disease,” says Brook Baker, a law specialist at Northeastern University in Boston, Massachusetts.
As the world’s main supplier of generic drugs, India is at the centre of the current patent fight.